Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Topiramate liquid formulation;Topiramate Sprinkle formulation · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Topiramate oral liquid formulation;Topiramate Sprinkle formulation | DRUG | - |
Inclusion Criteria: * Body mass index (BMI) between 19 and 32 kg/m2, inclusive * Women of non-child-bearing potential or practicing birth control * Have a normal electrocardiogram (ECG) * Be in good health, in the opinion of the investigator * Be sufficiently alert to understand and communicate int...
Top 9 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. | XENE | 4 | PHASE3 | Azetukalner |
| Praxis Precision Medicines, Inc. | PRAX | 5 | PHASE3 | Vormatrigine, Elsunersen |
| Rapport Therapeutics, Inc. | RAPP | 3 | PHASE3 | RAP-219 |
| Supernus Pharmaceuticals, Inc. | SUPN | 4 | PHASE2 | SPN-817, BIS-001ER |
| Biohaven Ltd. | BHVN | 3 | PHASE2 | BHV-7000 |
| Harmony Biosciences Holdings, Inc. | HRMY | 1 | PHASE3 | Clemizole |
| Jazz Pharmaceuticals Public Limited Company | JAZZ | 3 | PHASE1 | CBD-OS, Epidiolex |
| Bright Minds Biosciences Inc. | DRUG | 1 | PHASE2 | BMB-101 |
| uniQure N.V. | QURE | 1 | PHASE1 | AMT-260 |
Topiramate oral liquid formulation is an investigational liquid dosage form of topiramate, a small molecule being developed by Johnson & Johnson (JNJ) for epilepsy. It is designed as an alternative to the marketed topiramate sprinkle capsule formulation. The program is in Phase 1 clinical development.
Topiramate oral liquid formulation is being developed for epilepsy. It is intended to provide a liquid dosing option for patients who may have difficulty swallowing capsules. The formulation is investigational and has been studied in healthy adult volunteers rather than in patients with epilepsy.
Topiramate oral liquid formulation targets AMPA and kainate glutamate receptors, specifically GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, and GRIK5. It acts as an antagonist at these receptors. This mechanism is consistent with the pharmacological profile of topiramate, a small molecule used in epilepsy.
Johnson & Johnson, ticker JNJ, is the developer of topiramate oral liquid formulation. The company is responsible for the clinical development of this investigational liquid dosage form of topiramate.
Topiramate oral liquid formulation is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The Phase 1 program has been completed, with no active trials currently listed.
Topiramate oral liquid formulation has been studied in one completed Phase 1 trial, NCT00701493. This bioavailability study compared the oral liquid formulation to the marketed sprinkle capsule formulation in 40 healthy adults. The trial was randomized, uncontrolled, and not double-blind.
No, topiramate oral liquid formulation and topiramate sprinkle formulation are different dosage forms. The liquid formulation is an investigational oral liquid, while the sprinkle formulation is a marketed capsule that can be sprinkled on food. Both contain topiramate and are developed by Johnson & Johnson.